[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-donors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-donors":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,73,94,117],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100100567","a-biospecimen-collection-study-of-leukapheresis-derived-circulating-tumor-cells-immune-cells-and-progenitor-cells-100100567",false,"NCT00571389","A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.","A Biospecimen Collection Study to Facilitate Development of an Ex-Vivo Device Platform for Culture, Immune Assay, and Biobanking of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.","Inclusion Criteria for Biospecimen(s) collection:\n\nCancer Cohort Inclusion Criteria:\n\n1. Male or Female Adult ≥ 18 years of age.\n2. Histological diagnosis of any solid tumor type and at any stage of disease progression including in the neoadjuvant\u002Fpresurgical setting, adjuvant setting, or considered in remission.\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 3 (see Appendix 2) and an estimated life expectancy of at least 3 months.\n4. Subject or subject's legal representative provides written informed consent.\n5. Negative serology screening test for HIV, Hepatitis B surface antigen, and Hepatitis C antibody, or negative reflex PCR test result for HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)\n6. Additional eligibility criteria need to be met for leukapheresis collection:\n\n   * ECOG Performance Status of 0 or 1 (see Appendix 2)\n   * WBC ≥2000\u002FμL\n   * Neutrophils ≥1000\u002FμL\n   * Platelets ≥100x103\u002FμL\n   * Hemoglobin ≥9 g\u002FdL\n   * Creatinine ≤2.5 x ULN\n   * AST ≤2.5 x ULN without, and ≤ 5 x ULN with hepatic metastases\n   * Bilirubin ≤2 x ULN (except patients with Gilbert's syndrome, who must have total bilirubin ≤ 3.0 mg\u002FdL)\n   * Negative urine pregnancy test for women of childbearing potential\n\nHealthy Volunteer Cohort Inclusion Criteria:\n\n1. Male or Female Adult ≥ 18 years of age.\n\n   ▪ Pediatric healthy volunteers from 5-17 years of age, with suspected or confirmed COVID-19 diagnosis by laboratory test will be eligible to participate in minimally invasive biospecimen collection procedures, as long as written parental consent has been obtained, and if applicable and technologically able, child assent. Minimally invasive biospecimen collection procedures allowed for pediatric participation include swabs (nasal, NP and OP), microcapillary sampling, and saliva or urine collection.\n2. Healthy volunteers are eligible, including the following:\n\n   * History of autoimmune disease or inflammatory disorder considered clinically stable by the Principal Investigator or treating physician's discretion.\n   * Suspected or diagnosed COVID-19 disease by laboratory test, whether in the acute, sub-acute or convalesced state.\n   * Employees of the study site(s) or BioCytics, as long as fulfilment of inclusion criteria 3.c is obtained.\n3. Subject or subject's legal representative provides written informed consent.\n4. Negative serology screening test for HIV, Hepatitis B surface antigen, and Hepatitis C antibody, or negative reflex PCR test result for HIV, HBV, and HCV.\n5. Additional eligibility criteria need to be met for leukapheresis collection:\n\n   * Must be ≥ 18 years of age.\n   * WBC ≥2000\u002FμL\n   * Neutrophils ≥1000\u002FμL\n   * Platelets ≥100x103\u002FμL\n   * Hemoglobin ≥9 g\u002FdL\n   * Creatinine ≤2.5 x ULN\n   * AST ≤2.5 x ULN\n   * Bilirubin ≤2 x ULN (except patients with Gilbert's syndrome, who must have total bilirubin ≤ 3.0 mg\u002FdL)\n   * Negative urine pregnancy test for women of childbearing potential\n\n2.3.4. Exclusion Criteria\n\n1. Subjects with active infection requiring therapy (fever, localizing source) will be excluded until the infection resolves.\n\n   a. This excludes subjects with suspected or confirmed COVID-19 by laboratory test while in the acute and sub-acute phase of viremia.\n2. Underlying medical condition that, in the Principal Investigator's or treating oncologist's opinion, will obscure the interpretation of the patient's safety.\n3. Confirmed positive reflex PCR test result for HIV, Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV).",true,"ALL","5 Years",{"count":20,"type":21},1500,"ESTIMATED","OBSERVATIONAL","Primary Objective:\n\nThis is a study to investigate the feasibility of harvesting, expanding, and selecting T lymphocytes from cancer patients and healthy volunteers. The preliminary objective of this study is aimed at selecting PD-1+ and CTLA4+ T cells and other cellular fractions from peripheral blood of cancer patients and healthy volunteers by using specific conjugated antibodies, evaluating their functional ex vivo anti-tumor cytotoxicity against targeted autologous tumor cells.",[25,26,27],"Solid Tumor, Adult","Healthy Donors","COVID-19 Donors",[29,30],"All Stages of cancer","All stages of solid tumor origin","RECRUITING","2026-03-16",{"date":34,"type":35},"2026-03-18","ACTUAL",{"date":37,"type":4},"2007-11",{"date":39,"type":21},"2030-02",{"name":41,"class":42},"BioCytics, Inc.","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100580223","phase-4-bioequivalence-study-of-clonazepam-2-mg-tablets-100580223","NCT06834503","Bioequivalence Study of Clonazepam 2 Mg Tablets","Bioequivalence Study of Clonazepam 2 Mg Tablets\u002Fimmediate Release Tablets in Healthy Subjects in a Fasting Condition","Clonazepam","Inclusion Criteria:\n\n* Women and men between 18 and 50 years of age at the time of signing the informed consent form.\n* Women who are not capable of conceiving (To be considered not capable of conceiving she must be at least 1 year postmenopausal or surgically sterile) or who are not pregnant or breastfeeding.\n* Women of childbearing capacity must be using adequate contraception for the past 6 months and agree to continue using adequate contraception for 30 days after signing the consent form.\n* Have been clinically diagnosed as healthy by the study physician.\n* Subjects with the clinical laboratory results requested in the protocol (Table 2) within normal ranges and\u002For fit by medical selection. Current for 3 months.\n* Subjects non-smokers for the last 3 months at the time of signing the informed consent.\n* Having signed the informed consent for the study.\n* Subjects sexually active or of reproductive age must use an effective contraceptive method during and for at least 7 days after the end of the study.\n* Body mass index between 18-30 kg\u002Fm2 at the time of inclusion in the study.\n* Subject with complete contact information (cell phone and\u002For landline contact, address).\n* Subject with a family member or guardian with a contact telephone number.\n* Subject with the availability of time to comply with the scheduled visits and activities.\n* Subject willing to comply with the prohibitions and restrictions specified in this protocol.\n\nExclusion Criteria:\n\n* Subject with a diagnosis of renal, cardiac, hepatic, immunological, dermatological, endocrine, gastrointestinal, neurological or psychiatric disease, compulsive depressive disorder.\n* Subject with diagnosis of hematological disorders, such as anemias and\u002For polycythemia.\n* Subjects with history of gastric surgeries.\n* Permanent or temporary use during the last 5 days prior to the administration of the investigational product of the study of any type of medication either on their own initiative or by medical prescription. Except female patients who are planning regularly with the same contraceptive method in the last 6 months prior to the start of the present study.\n* Pregnant or breastfeeding women (Table 2).\n* Xanthine consumption from coffee, tea or chocolate during the 48 hours prior to hospitalization.\n* Alcohol consumption of more than 16 g per week equivalent to 1 beer or 2 glasses of wine during the 5 days prior to administration of the investigational product.\n* Positive test for consumption of drugs of abuse or psychoactive substances at the time of screening or prior to administration of the investigational product. (Table 2)\n* Known hypersensitivity to the active substance or excipients of the test product.\n* Medical history of angioedema or anaphylaxis.\n* Subject diagnosed with human immunodeficiency virus, hepatitis B (surface antigen) or hepatitis C (surface antigen) positive infection.\n* Having participated in clinical trials in the 4 months prior to the time of signing the informed consent.\n* Have donated blood or reported blood loss greater than 500 mL in the 30 days prior to the time of investigational product administration.\n* Subject with clinically significant acute illness or temperature \\> 38°C within 24 hours prior to administration of the investigational product.\n* Subject with any contraindication to blood collection due to bleeding disorders or thrombocytopenia.","18 Years","50 Years",{"count":55,"type":21},24,"INTERVENTIONAL",[58],"PHASE4","Demonstrate the bioequivalence in 1 study, in fasting condition of two formulations of clonazepam 2 mg Tablets \u002F tablets immediate release in order to establish that there are no significant pharmacokinetic differences.",[61,26],"Healthy","NOT_YET_RECRUITING","2025-03-05",{"date":65,"type":35},"2025-03-10",{"date":67,"type":21},"2025-06-10",{"date":69,"type":21},"2025-11-01",{"name":71,"class":72},"Centro de Atencion e Investigacion Medica","NETWORK",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":16,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":43},"100580830","novel-targets-for-the-development-of-monoclonal-antibodies-for-immunotherapy-100580830","NCT06842407","Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)","Nuovi Bersagli Per lo Sviluppo di Anticorpi Monoclonali Per Immunoterapia - (Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)","Immuno-ab","Inclusion Criteria:\n\n* blood donors\n* age of 18 years or more\n* able to sign informed consent\n\nExclusion Criteria:\n\n* age below 18 years\n* Positive for HIV, HCV, HBV\n* not suitable for blood donation\n* not able to understand or sign informed consent",{"count":82,"type":21},600,"The first objective of the project consists in the preclinical validation of new possible molecular targets associated with intratumoral T regulatory cells. The second objective consists in the selection of monoclonal antibodies with therapeutic potential, specific for the selected targets.",[26],"2025-02-19",{"date":87,"type":35},"2025-02-24",{"date":89,"type":35},"2023-04-01",{"date":91,"type":21},"2026-06-30",{"name":93,"class":42},"Checkmab S.r.l.",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":16,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":102,"targetDuration":4,"studyType":56,"phases":104,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100579366","phase-4-bioequivalence-study-of-pentoxifylline-400-mg-in-healthy-subjects-under-fasting-and-fed-conditions-100579366","NCT06823362","Bioequivalence Study of Pentoxifylline 400 Mg in Healthy Subjects Under Fasting and Fed Conditions","Bioequivalence Study of Pentoxifylline 400 Mg in Sustained Release Tablets in Sustained Release Tablets in Healthy Subjects Under Fasting and Fed Conditions","Pentoxifylline","Inclusion Criteria:\n\n* Men or women between 18 and 50 years of age at the time of signing the informed consent form.\n\ninformed consent. - Women who are not able to conceive, who are not pregnant or breastfeeding. (To be considered not able to conceive she must be at least 1 year postmenopausal).\n\npostmenopausal for at least 1 year or be surgically sterile). Table 2.\n\n* Female participants who are capable of conceiving must be using adequate contraceptive methods for the adequate contraceptive methods for the past 6 months and agree to continue using an adequate method of contraception for the adequate contraceptive method for 30 days after signing the consent form.\n* Have been clinically diagnosed as healthy by the study physician.\n* Subjects with clinical laboratory results within the normal range and\u002For fit by medical medical selection. (Table 2)\n* Subjects were non-smokers for the last 3 months at the time of screening.\n* Having signed the informed consent for the study.\n* Body mass index between 18-30 kg\u002Fm2.\n* Subject with complete contact information (cell phone and\u002For landline contact, address).\n* Subject who has a family member or guardian with a contact telephone number.\n* Subject with the availability of time to comply with the scheduled visits and activities.\n* Subject who is willing to comply with the prohibitions and restrictions specified in this protocol.\n\nExclusion Criteria:\n\n* Subject diagnosed with renal, cardiac, hepatic, immunologic, dermatologic, endocrine, gastrointestinal, neurologic or psychiatric disease, endocrine, gastrointestinal, neurological or psychiatric disease.\n* Subject with diagnosis of hematological disorders, such as anemias and\u002For polycythemia.\n* Subjects with a history of gastric surgery.\n* Permanent or temporary use during the last 15 days of any type of medication. days prior to the administration of the drug, either on their own initiative or by medical prescription.\n\nmedical prescription. Except female patients who are planning regularly with the same contraceptive method.\n\nthe same contraceptive method in the last 6 months prior to the start of the present study.\n\nthe present study.\n\n\\- Smoker in the last 3 months, regardless of the number of cigarettes at the time of selection.\n\nselection.\n\n* Consumption of xanthines from coffee, tea or chocolate during the previous 48 hours.\n* Drinking alcohol in excess of 16 g 15 days prior to administration of the investigational drug.\n\nequivalent to 1 beer or 2 glasses of wine.\n\n* Positive test for the consumption of drugs of abuse or psychoactive substances at the time of screening or prior to administration of the (Table 2).\n* Known hypersensitivity to the active substance or excipients of the test product.\n* Medical history of angioedema or anaphylaxis.\n* Pregnant or lactating woman.\n* Subject diagnosed with human immunodeficiency virus, hepatitis B or hepatitis C positive.\n\nhepatitis C positive.\n\n* Having participated in clinical studies in the 4 months prior to the start of the present study.\n* Having donated blood or reported blood loss of more than 500 mL in the 30 days prior to subject selection.\n\nprior to subject selection.\n\n* Subject has a clinically significant acute illness or temperature \\> 38°C within 24 hours prior to the within 24 hours prior to investigational product administration.\n* Subject has a contraindication to blood collection due to bleeding or thrombotic disorders.\n\nbleeding disorders or thrombocytopenia.",{"count":103,"type":21},40,[58],"Two bioequivalence studies of Pentoxifylline will be carried out in 40 healthy subjects, the first in a fasting condition 40 healthy subjects, the first in fasting condition and the second in postprandial condition.\n\npostprandial condition, the two studies follow the same design: Complete crossover design, randomized, comparative of two study formulations, in single dose of 400 mg of Pentoxifylline sustained release tablets, 2 periods, with a washout time of 7 days between doses, the 7 days between doses, participation as a subject in these studies involves a risk studies involves a higher than minimal risk for subjects.",[61,26],[108],"Bioequivalence","2025-02-13",{"date":111,"type":35},"2025-02-17",{"date":113,"type":21},"2025-04-10",{"date":115,"type":21},"2025-09-30",{"name":71,"class":72},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":16,"sex":17,"minAge":52,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":56,"phases":126,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":43},"100572827","investigating-the-impact-of-the-seaweed-derived-food-additive-carrageenan-on-the-human-gut-microbiome-100572827","NCT06738329","Investigating the Impact of the Seaweed Derived Food Additive, Carrageenan, on the Human Gut Microbiome","Inclusion Criteria:\n\n* Healthy individuals\n\nExclusion Criteria:\n\n* Prescribed antibiotics in the last 3 months\n* Individuals with any gut disorders such as IBS or IBD\n* individuals with any food allergies or intolerances\n* Individuals who regularly consume pre or probiotics","55 Years",{"count":125,"type":21},99,[127],"NA","The goal of this study is to investigate whether a seaweed derived food additive, carrageenan, has an impact on the human gut microbiome in vivo. The primary purpose is to assess whether consumption of a carrageenan containing product for 4 weeks can alter the bacterial composition of the gut microbiome in healthy individuals and whether the addition of a prebiotic fibre, inulin, to the product has an enhanced beneficial impact of the gut composition. The main questions to answer are:\n\nDoes the consumption of a confectionary item containing carrageenan and inulin lead to a positive impact on the faecal microbial community when compared to the confectionary item containing no carrageenan and no inulin (placebo)? Participants will be asked to consume 2 gummy sweets for 4 week period and provide stool and urine samples on 3 occasions over a 9 week period.\n\nDoes the consumption of a confectionary item containing carrageenan and inulin improve gastrointestinal comfort measured using overall SHS-GI score when compared to baseline measurements recorded during run in period?",[130,26],"Gut Microbiome",[132,133,134,135],"Carrageenan","Gut microbiome","Gut health","food additive","2024-12-12",{"date":138,"type":35},"2024-12-17",{"date":140,"type":35},"2024-10-01",{"date":142,"type":21},"2025-05-30",{"name":144,"class":145},"University of Reading","OTHER"]